Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data

7 August 2026 · By · Wire by Fusion42

Published

7 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 8 August 2026 · Fusion42 review

BioInvent's BI-1808 received FDA Fast Track designation for treating platinum-resistant ovarian cancer in combination with pembrolizumab, supported by Phase 2a data showing improved response rates without chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 7 Aug 2026 and 10 Aug 2026.

◆ ◆ The Wire takeaway

You now face a new benchmark in platinum-resistant ovarian cancer treatment that excludes chemotherapy. Drug developers in immuno-oncology must accelerate combination strategies targeting TNFR2 alongside PD-1 to stay relevant.

◆ Coverage

3 sources · first reported 7 Aug 2026 · latest 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-fast-trackovarian-cancerbiotechclinical-trialsimmunotherapy